Ansell (ASX:ANN) Proves It Can Pass On Trump’s Tariffs – But With Shares Down 13%, Is It a Buy?

Ansell Shrugs Off Tariffs with Strong Pricing Power

Ansell (ASX: ANN) reported half-year results on Monday that told a story most ASX investors weren’t expecting. Revenue barely moved, up just 0.7% to US$1.03 billion, yet adjusted net profit surged 18% to US$95.7 million. The gap between those two numbers reveals something important: this is a business with genuine pricing power. Ansell absorbed roughly US$80 million in annualised Trump tariff costs across its Malaysian, Thai, Sri Lankan and Vietnamese factories and passed nearly all of it through to customers with “very limited” pushback.

For investors who watched several high-profile ASX healthcare names struggle this reporting season, Ansell’s result is a reminder that not all healthcare stocks are suffering; some are quietly getting stronger.

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

How Ansell Turned a US$80 m Tariff Hit Into a Profit Beat

With a significant share of revenue coming from the US market and manufacturing spread across Southeast Asia, Ansell was squarely in the firing line of Trump’s tariffs. The company implemented two waves of price increases, the first around mid-2025 and the second by the end of calendar year 2025, and they stuck. Outgoing CEO Neil Salmon said pushback mainly came from low-margin, basic products, not from Ansell’s core range.

This shows real pricing power, driven by a simple fact: protective gloves and safety gear are essential. Hospitals, labs, and chemical plants cannot cut back on these products. That gives Ansell pricing strength that most ASX-listed companies do not have.

The numbers backed this up. EBIT margin rose by 180 basis points to 14.3%, helped by savings from the Kimberly-Clark Business Unit, which hit its US$50 million annual synergy target. Cash conversion was a strong 112%, and net debt-to-EBITDA improved to a healthy 1.5 times, even after US$47 million was spent on share buybacks during the half.

New CEO Takes Over a Strong Business, But Revenue Growth Is Missing

Nathalie Ahlström officially replaced Neil Salmon as CEO on Monday, inheriting a business at all-time EBIT highs with a clean balance sheet. She described Ansell as “much more focused, efficient, and really well positioned.”

However, the top line tells a different story. Organic sales actually declined 0.6%. Management adjusts for US$27 million in one-off prior-year order benefits and says “true” growth was closer to 2%, but investors will want to see real headline revenue acceleration before getting excited. Until Ansell can show it’s growing the business and not just growing margins, the re-rating potential stays limited. The new CEO’s priorities- innovation, the Ansell Guardian platform, and the ERP rollout- are the right ones, but they’ll take time to show results.

The Investor’s Takeaway

While the stock has struggled over the past year, Monday’s positive market reaction to the profit beat suggests that the ‘tariff-risk’ discount is finally beginning to unwind.

Here’s the disconnect: Ansell’s stock is down roughly 13% over the past year despite delivering 18% profit growth. We believe the market has focused too much on the tariff risk headline and not enough on the actual result, which shows Ansell can handle tariffs effectively. 

At around 16 times forward earnings with double-digit EPS growth and a healthy balance sheet, the valuation doesn’t look stretched. FY26 adjusted EPS guidance of US137-149 cents was maintained, not upgraded, which suggests management is being conservative. For investors comfortable with the USD-denominated, unfranked dividend structure, current levels look like a reasonable entry point.

That said, until we see genuine revenue acceleration under the new CEO, the upside may be capped. The key risk is further tariff escalation that exceeds pricing power limits. The key watch is whether organic revenue turns positive in the second half and whether Ahlström signals any strategic shift.